[
  {
    "condition": "obesity",
    "global_market_size_usd_bn": 25.4,
    "forecast_market_size_usd_bn_2030": 68.0,
    "cagr_percent": 18.5,
    "patient_population_millions": 650,
    "treated_population_percent": 6.2,
    "number_of_competitors": 8,
    "branded_vs_generic_mix": "branded-dominant",
    "key_competitor_classes": [
      "GLP-1 agonists",
      "Dual GLP-1/GIP"
    ],
    "commercial_signals": [
      "Strong payer uptake in US and EU",
      "Supply constraints impacting near-term sales"
    ],
    "risks": [
      "Pricing pressure from next-generation incretins",
      "Long-term cardiovascular outcomes scrutiny"
    ]
  },
  {
    "condition": "type 2 diabetes",
    "global_market_size_usd_bn": 45.0,
    "forecast_market_size_usd_bn_2030": 72.5,
    "cagr_percent": 9.8,
    "patient_population_millions": 420,
    "treated_population_percent": 28.0,
    "number_of_competitors": 12,
    "branded_vs_generic_mix": "branded-heavy",
    "key_competitor_classes": [
      "GLP-1 agonists",
      "Insulin",
      "SGLT2 inhibitors"
    ],
    "commercial_signals": [
      "GLP-1s shifting standard of care",
      "Strong guideline support"
    ],
    "risks": [
      "Formulary exclusions in price-sensitive markets"
    ]
  },
  {
    "condition": "nonalcoholic steatohepatitis",
    "global_market_size_usd_bn": 6.2,
    "forecast_market_size_usd_bn_2030": 21.0,
    "cagr_percent": 22.1,
    "patient_population_millions": 115,
    "treated_population_percent": 2.5,
    "number_of_competitors": 15,
    "branded_vs_generic_mix": "generic-heavy",
    "key_competitor_classes": [
      "Metabolic modulators",
      "FXR agonists"
    ],
    "commercial_signals": [
      "High unmet need with no approved therapies",
      "Multiple late-stage pipeline assets"
    ],
    "risks": [
      "High clinical failure rates in NASH",
      "Regulatory uncertainty on endpoints"
    ]
  }
]
